
Novartis has revealed that its arthritis drug, theinterleukin-1 beta inhibitor canakinumab, in combination with standard of care (SoC), failed to …
The FDA has asked Novartis for more information on its gouty arthritis drug canakinumab. The regulator’s request came in a …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

